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Dedication ((optional)) 
Abstract: The convenient preparation of three imidazo[1,2-
a]pyridine-2-carboxamide intermediates is reported through known 
Strecker‒Ugi type multicomponent reactions, Tschitschibabin type 
condensations and further synthetic sequences. The derivatives were 
then efficiently converted to novel 4-chloro-2-
(trifluoromethyl)pyrido[1,2-e]purines by way of their original reactions 
with 2,2,2-trifluoroacetamide, followed by subsequent 
dehydroxychlorination reactions. These compounds were cross-
coupled under microwave irradiation through Suzuki‒Miyaura and 
Sonogashira palladium(0) catalysis to various aromatic and alkynyl 
reagents, thus providing the related C-4 substituted pyrido[1,2-
e]purines of biological interest in good yields. 
Introduction 
Purines are essential ubiquitous heterocyclic aromatic 
compounds that consist of a pyrimidine molecule fused to an 
imidazole ring. They are the most abundant nitrogen-containing 
heterocycles in nature,[1] and accordingly exhibit crucial roles. 
They display wide range of biological activities in various cellular 
processes involving DNA and RNA, ATP, GTP, cyclic AMP, 
NADH, and coenzyme A.[1-2] 
Since the early 1900’s,[3] the purine class of compounds have 
therefore spurred curiosity from the medicinal and organic 
synthetic chemistry community in generating analogs of variously 
substituted (heterocyclic) purines of biological interest.[4] 
Noteworthy, for some specific pharmacological activities, 
purine derivatives have been found to be less potent, while their 
surrogates with an additional fused ring motif have been shown to 
possess better pharmacokinetic profiles, enhanced 
pharmacological activities and significant physicochemical 
properties.[5] The fused and extended imidazopyridines and their 
related compounds may indeed serve as valuable tools in 
chemical biology, as many polycyclic nucleosides are 
fluorescent.[6] Moreover, important activities have been 
emphasized, such as antihypertension,[7] anti-inflammatory,[5a] 
human A3 adenosine receptor antagonism,[5b‒e,8] and inhibition of 
PDE1/5 and tyrosine kinase EphB4.[9,5f] 
Pyrido[1,2-e]purines of type 1 have hence recently gained 
attention in this direction. The new chemical entities have been 
shown to behave as powerful PDE5 inhibitors,[9b-d] of which some 
had a better selectivity over PDE6 and PDE1 than sildenafil,[9b] 
anticancer agents able to induce apoptosis of certain cancer cell 
lines or intercalating drugs to fit between base pairs of 
oligodeoxynucleotides.[5g,10] 
 
Figure 1. Synthetic routes to pyrido[1,2-e]purines. 
As illustrated in Fig. 1, the classical methods for the 
preparation of pyrido[1,2-e]purines commonly involve the 
formation of a suitably functionalized imidazo[1,2-a]pyridine 
system 2 (R2 = NO, NO2, NH2; R3 = C≡N, CO2R, CONH2),[11] 
followed by construction of the C2‒C3 annulated pyrimidine ring 
(path a).[5g,9b,10b,12] Various chemical approaches have been used 
in this respect, to give 2 in moderate to good yields, from 
substituted 2-aminopyridines and Tschitschibabin 
condensations,[9b,13] or Strecker‒Ugi type cascade 
reactions.[5g,12a] Ehrlich-Sachs type cyclizations of 2-
nitrosopyridines were also used, albeit with much lower 
efficiencies.[10b,12b,14] The imidazo[1,2-a]pyridine derivatives 2 
could then be reacted with guanidine, formamide, acetamidine 
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acetate, triethyl orthoformate, ammonium formate, or acyl 
chloride reagents to give, after few other reactions, the expected 
pyrido[1,2-e]purines of type 1. 
As miscellaneous, compounds 1 may also be readily available 
through few synthetic sequences and (i) ring-closing metathesis 
of 8,9-diallyl-6-chloro-purine 3 (path b),[10g] (ii) silver-catalyzed 
intramolecular hydroamination of terminal alkynes of type 4 (path 
c),[15] (iii) double C‒H arylations of 9-phenylpurines 5, or (iv) 
consecutive Suzuki-Miyaura and direct C‒H arylation of 9-(2-
bromophenyl)purines 6 (path b).[16] Intramolecular cyclization 
reactions of 1,3-bis(4-methoxybenzyl)-5-(pyridin-2-
ylamino)pyrimidine-2,4(1H,3H)-diones 7 could be performed 
otherwise (path d).[17] 
Worth noting, oxidatively damaged DNA, which result from the 
attack of sugar and base moieties by reactive oxygen species 
(ROS) are formed as byproducts of normal cell metabolism and 
during exposure to endogenous or exogenous chemical or 
physical agents. Guanine, having the lowest redox potential, is 
the DNA base the most susceptible to oxidation, yielding 
mutagenic 8-oxo-7,8-dihydroguanine (8-oxoG). In eukaryotic cells, 
8-oxoG is primarily repaired by the base excision repair pathway 
(BER) initiated by the DNA N-glycosylase hOGG1.[18] Human 
molecular and epidemiological studies have shown that hOGG1 
can affect significantly cancer proliferation and other diseases 
development, such as Neurodegenerative diseases (NDD).[19,20] 
hOGG1 is therefore considered as a pertinent pharmalogical 
target.[20,21] 
Along our ongoing research program directed at generating 
small molecule modulators of hOGG1, we were interested in the 
synthesis of pyrido[1,2-e]purine scaffolds that would feature a CF3 
substituent at C-2 and an aromatic functional group at C-4 that 
would possibly be connected via a rigid carbon‒carbon (Csp2‒
Csp) bond. Surprisingly, there is no example of such derivatives 
in the literature so far. 
Herein, we thus report our studies concerning the 
straightforward and efficient preparation of such compounds (i.e., 
A). 
Results and Discussion 
Synthesis 
 
Figure 2. Retrosynthetic planning. 
As depicted here above (Fig. 2), our retrosynthetic planning for 
the making of compounds A follows path a (e.g., Fig. 1). It 
requires novel 4-chloro-2-(trifluoromethyl)pyrido[1,2-e]purines B 
that would be derivatized through Pd-catalyzed cross-coupling 
chemistry. The synthesis of B would in turn, be achieved through 
dehydroxychlorination of hitherto unknown 2-
(trifluoromethyl)pyrido[1,2-e]purin-4-ol derivatives C, obtained 
from the original reactions of imidazo[1,2-a]pyridine-2-
carboxamides D and 2,2,2-trifluoroacetamide (CF3(CO)NH2). 
Carboxamides D would be readily prepared, using known reaction 
sequences from commercial heterocyclic 2-amidines E. 
 
 
Scheme 1. Synthesis of 4-chloro-2-(trifluoromethyl)pyrido[1,2-e]purine derivatives 17a‒17c. 
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A set of aminoimidazo[1,2-a]pyridine-2-carboxamides 8a‒8c 
(R1 = H (a), 4-Me (b), 5-Me (c)) were thus generated as model 
substrates (Scheme 1). Following a desilylative Strecker‒Ugi type 
multicomponent reaction, the 2-aminopyridine 9a was reacted 
with ethylglyoxalate 10 in the presence of TMSCN and 1,4-
diazabicyclo[2.2.2]octane (DABCO) under microwave irradiation 
(120 °C) to give 11a in moderate yield (60%).[5g,12a] 8a was 
afforded by subsequent reaction with aqueous ammonia at 70 °C 
for 48 h (81%). Compounds 8b and 8c were prepared otherwise 
according to a Tschitschibabin type condensation protocol.[9b] 
Aminopyridines 9b and 9c were therefore converted into 
imidazo[1,2-a]pyridine-2-carboxylates 12b (50%) and 12c (60%) 
respectively, by refluxing in EtOH (route a) or MeOH (route b) with 
ethyl bromopyruvate 13. The regioselective nitrations (e.g., 
H2SO4/HNO3) of 12b‒c were then performed at 0 °C to provide 
the mono-nitro products 14b‒c in good yields (81 vs. 70%). Next, 
the nitroesters 14b‒c were stirred in a mixture of aqueous 
ammonia and THF at room temperature, to provide nitroamides 
15b‒c in excellent yields (90 and 91%). Reductions of 15b‒c to 
the corresponding aminoamides 8b‒c were achieved by catalytic 
hydrogenation (10% Pd‒C, rt, route c), or treatment with Tin(II) 
chloride in EtOH at 100 °C under μW irradiation (route d).[9b] From 
the pyridine-carboxamide intermediates 8a‒8c, annulation and 
chlorination reactions were then carried out by heating at 160 °C 
with CF3(CO)NH2 used as solvent (24 h) and treatment with an 
excess of SOCl2 under reflux (1.5 h). The 2-
(trifluoromethyl)pyrido[1,2-e]purin-4-ol derivatives 16a‒16c (58-
73%) and 4-chloro-2-(trifluoromethyl)pyrido[1,2-e]purines 17a‒
17c were obtained in moderate to good yields (i.e., 60-77%). 
Compounds 17a‒17c in hands we decided to investigate further 
post-modification of the pyrimidine substitution pattern. Easy 
post-decoration of 4-chloro-pyrido[1,2-e]purines through 
nucleophilic substitutions with (aryl)- amines, alcohols and thiol 
reagents has already been described;[5g,12a] but to the best of our 
knowledge, there is no mention of their transition-metal catalyzed 
cross-coupling reactions with C-Nu. 
The Suzuki−Miyaura reaction is a cornerstone of modern 
organic synthesis. Unlike many cross-coupling strategies, it is a 
routine, versatile and benign reaction that is cost-effective, 
scalable and maybe amenable to green chemistry principles and 
industrial standards.[22] It was successfully applied to many 
different coupling partners, including nitrogen-containing 
heterocycles using catalytic amount of palladium(II) acetate (0.1 
eq.), Xantphos (0.2 eq.) as ligand and potassium carbonate (2 
equiv.) as base in toluene at elevated temperature. In addition, 
conventional thermal heating could be replaced by microwave 
irradiation in a sealed reactor with major improvement in terms of 
yields and reaction times.[23] These conditions were thus tested 
with p-tolylboronic acid and chloropurine 17a as model substrate 
to give 18a in good yield (85%) after 50 min of reaction at 100 °C 
(Table 1, entry 1). Triphenyl phosphine, and BINAP,[24] together 
with Xantphos,[25] have become the most often used ligands for 
palladium-catalyzed carbon‒carbon and the more challenging 
carbon‒nitrogen bond-forming reactions.[26,27] Thus, subsequent 
cross-coupling reactions were next conducted with PPh3 and 
BINAP, but a disappointing yield decrease was noticed (entries 2-
3). Of note, in situ generation of 
tetrakis(triphenylphosphine)palladium(0) through insertion of 
Pd(OAc)2 and PPh3 (entry 2) vs. direct addition of Pd(PPh3)4 
(entry 4) did not produce any variation of the reaction yield (ca. 
80%). When the influence of the solvent was assessed (H2O, 
H2O/DME, 1,4-dioxane), slight to dramatic decrease of the 
catalytic efficiency was noted (entries 5-7). It was also the case 
when Cs2CO3 was replaced by K2CO3 as base (entry 8). Finally, 
reaction temperature was increased to 120 °C to give a 
satisfactory 84% yield after a period of reaction of 30 min (entry 
9). Interestingly, there was no cross-coupling reaction without a 
catalyst (entry 10), which excludes an addition/elimination 
pathway. 
 
Table 1. Optimization of the conditions for the Suzuki‒Miyaura coupling 
reaction of p-tolylboronic acid and compound 17a.[a] 
 
Entry Catalyst Ligand Solvent Yield (%) 
of 18a 
1 Pd(OAc)2 Xantphos toluene 85 
2 Pd(OAc)2 PPh3 toluene 80 
3 Pd(OAc)2 BINAP toluene 60 
4 Pd(PPh3)4 ‒ toluene 79 
5 Pd(OAc)2 Xantphos H2O 50 
6 Pd(OAc)2 Xantphos H2O/DME 40 
7 Pd(OAc)2 Xantphos 1,4-dioxane 70 
8 Pd(OAc)2 Xantphos toluene 77[b] 
9 Pd(OAc)2 Xantphos toluene 84[c] 
10 Pd(OAc)2 ‒ toluene traces 
[a] Typical reaction conditions: Ar atmosphere, compound 17a (1 eq.), p-
tolylboronic acid (1.5 eq.), K2CO3 (2 eq.) as base, catalyst (0.1 eq.), 
additional ligand (0.2 eq.), heating at 100 °C under microwave irradiation for 
50 min in a sealed reactor. [b] Cs2CO3 (2 eq.) instead of K2CO3 (2 eq.) were 
added. [c] Heating was performed at 120 °C for 30 min. 
 
The scope of the reaction was then explored using various 
organoboronic acids under the optimized aforementioned 
conditions (entry 9). As depicted in Scheme 2, yields obtained 
were good for most products (e.g., 65-85%). It is worth noting that 
a better reactivity was observed for boronic acids substituted with 
a methyl or an electron-withdrawing group. The outcomes were 
also indicative of the influence of the substituent position on the 
reactivity of the boronic acid. Comparing the same moiety, the p-
substituted phenylboronic acid showed better reactivity than the 
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respective m- and o-substituted phenylboronic acids. 
Furthermore, substitution by a methyl group at the C-7 or C-8 
position of compounds 17 did not change significantly the yield of 
the catalysis. 
 
Scheme 2. Scope of the Suzuki‒Miyaura Reaction. 
Having successfully established the efficacy of the Suzuki‒
Miyaura in constructing trifluoro purines with aromatic 
substituents at C-4 with a Csp2‒Csp2 bond, we next turned our 
attention to a palladium‒catalyzed process allowing construction 
of Csp2‒Csp bonds. The Sonogashira reaction has found 
extensive use in this respect, in natural products synthesis and for 
the making of complex molecules.[28] Various solvents, palladium 
species, copper(I) salts and bases were tested. Remarkably, few 
examples have been reported on halogeno[1,2-a]pyridines,[29] 
due to their possible antiviral, anticancer, antiulcer, antifungal and 
antibacterial properties. The substituted [1,2-a]pyridine 
compounds may also find applications as calcium channel 
blockers, benzodiazepine receptor agonists, herbicides, GABAA 
receptor modulators, and cyclin-dependent kinase (CDK) 
inhibitors, etc.,.[30] In some instances, PdCl2(PPh3)2 (0.05 eq.), 
Pd(OAc)2 (0.05 eq.) and PPh3 (0.1 eq.) or Pd(PPh3)4 (0.05 eq.) as 
catalysts were used with CuI (0.2 eq.) as co-catalyst in a mixture 
of DMF/Et3N (1:1, v/v) at 50 °C.[29,31] These conditions were thus 
employed with 17a and ethynylbenzene to give moderate to good 
yields (45-70%, Table 2, entries 1-3) of purine 27a after 60 min of 
reaction. Total conversion was observed with 1.2 eq. of the 
alkynyl reagent and 1 eq. of 17a, as monitored by TLC analysis 
of the crude reaction mixtures. The amount of the copper(I) iodide 
salt proved to be crucial, as it was not amenable to a lower loading 
without loss of the catalysis efficiency (55% vs. 70%, entries 3-4). 
Heating under microwave irradiation was also studied in order to 
improve the yields and to decrease reaction times.[23a-b] Notable, 
a 65% yield was obtained over 5 min of reaction at 90 °C (entry 
5), whereas a satisfactory 75% of product 27a was afforded after 
15 min at 70 °C (entry 5). The deprotonation of the acetylene may 
be an important step at the beginning of the cross-coupling 
reaction. However, the use of other bases (Cs2CO3, HN-i-Pr2, 
KOt-Bu, etc;,) was not explored. At that stage, we thought the 
conditions were acceptable to be evaluated with compounds 17a‒
c and a range of variously substituted alkynyl (aromatic) reagents. 
Gratifyingly, yields of the coupled derivatives 27‒34 were quite 
good for most products, as shown in Scheme 3. As expected, the 
stereoelectronic properties of the acetylenes were correlated with 
the performance in alkynylation reactions. As a rule, the 
arylacetylene with the most 4-R electron-donating ability 
produces the best chemical yield (OMe > H > Me > F, see 
compounds 28a‒30a, 34a). Interestingly, it is the opposite of 
Plenio investigations on electronic effects for Tolanes 
synthesis.[32] 
 
Table 2. Optimization of the conditions for the Sonogashira coupling reaction 
of ethynylbenzene and compound 17a.[a] 
 
Entry Catalyst Ligand Time (min) Yield (%) of 
27a[a] 
1 Pd(OAc)2 PPh3 60 45[b] 
2 Pd(PPh3)4 ‒ 60 62 
3 Pd(PPh3)2Cl2 ‒ 60 70 
4 Pd(PPh3)2Cl2 ‒ 60 55[c] 
5 Pd(PPh3)2Cl2 ‒ 5 65[d] 
6 Pd(PPh3)2Cl2 ‒ 15 75[e] 
[a] Typical reaction conditions: Ar atmosphere, compound 17a (1 eq.), 
ethynylbenzene (1.2 eq.), catalyst (0.05 eq.), copper(I) iodide (0.2 eq.), 
heating at 50 °C. [b] Pd(OAc)2 (0.05 eq.) as catalyst and PPh3 (0.1 eq.) as 
ligand were used. [c] CuI (0.1 eq.) was used as co-catalyst instead of CuI 
(0.2 eq.). [d] Heating was performed at 90 °C under W irradiation. [e] 
Heating was performed at 70 °C under W irradiation. 
 
Comparing the same moiety, the p-substituted phenylalkynes 
showed enhanced product formation as regard to the o-
derivatives. The m-substituted ones behave in the medium range 
with slightly similar overall yield than the p-substituted compounds 
(74% vs. 80% for 30a (o-MeOPh) and 32a (p-MeOPh)). 
Noteworthy, substitution by a methyl group at the C-7 position of 
compounds 17 did not affect significantly the yield of the cross-
coupled products (see 28b and 32b) while substitution at C-8 (i.e., 
17c) gave no conversion. The starting materials were fully 
recovered when reactions were attempted with 3-ethynylanisole 
and 4-ethynyltoluene (e.g., 28c and 32c). 
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Scheme 3. Scope of the Sonogashira Reaction. 
Conclusions 
In conclusion, we have reported an efficient and easy way to 
provide novel pyrido[1,2-e]purine derivatives featuring a 
trifluoromethyl substituent at C-2 and an aromatic functional 
group at C-4. The valuable synthetic routes were developed 
through reaction sequences from commercial heterocyclic 2-
amidines to give original 4-chloro-2-(trifluoromethyl)pyrido[1,2-
e]purine intermediates 17a‒c. Compounds 17a‒c were then 
further functionalized by Suzuki‒Miyaura and Sonogashira 
palladium(0) catalysis, under microwave irradiation to give 
compounds of type 18‒26 and 27‒34 in moderate to good yields. 
Of note, the cross-coupling reactions exhibited a high functional 
group tolerance, being reproducible for a wide range of 
arylboronic acids and (aryl) alkynyl reagents. In general, 
substitution at C-7 or C-8 position of the chloropurines (e.g., 17b‒
c) could be tolerated albeit it was not the case for the alkynylation 
reactions of compound 17c and 3-ethynylanisole or 4-
ethynyltoluene. Complementary studies to synthesize these 
important molecules are ongoing and biological evaluations on 
the 8-oxoguanine-DNA N-glycosylase hOGG1 isoform will be 
reported in due course. 
Experimental Section 
General Remarks. Unless otherwise stated, all solvents and commercially 
available reagents were used as purchased. N,N-Dimethylformamide 
anhydrous, 99.8% was purchased from Sigma‒Aldrich. Thionyl chloride 
(SOCl2) was distilled prior to use. Reactions were monitored by thin-layer 
chromatography (TLC) using Merck Silica Gel 60 F254 pre-coated plates. 
Visualization of the developed chromatogram was performed under 
ultraviolet light (254 nm) and on staining by immersion in aqueous, acidic 
ceric ammonium molybdate (CAM; 470 mL H2O, 28 mL H2SO4, 24 g 
ammonium molybdate, 0.5 g cerium ammonium nitrate) followed by 
heating on a hot plate. Normal phase flash chromatography was performed 
in air on Silica Gel 60 (230–400 mesh). Organic solutions were 
concentrated under reduced pressure with a Buchi rotary evaporator. 
Microwave activations were performed in sealed vessels using a Biotage 
Initiator system. The following settings were used: Normal absorption level, 
Fixed Hold Time: on. The internal temperature was measured by an IR-
sensor. NMR spectra were recorded at 298 K with a Bruker Avance III HD 
nanobay 400 MHz spectrometer equipped with a PABBO BBO probe, a 
Bruker Avance II and a Bruker DPX 250 MHz spectrometer. The nuclei-
signal assignments were done with the aid of 1 D [1H NMR, 13C NMR, 
Distortionless Enhancement by Polarization Transfer (DEPT)] and 2 D 
Correlation Spectroscopy [(1H–1H COSY and 1H–13C Heteronuclear Single 
Quantum Coherence (HSQC)] experiments. When appropriate or in case 
of ambiguous proton and carbon, assignments were established using 19F 
NMR and Heteronuclear Multiple-bond Correlation (HMBC). 13C and 19F 
spectra were acquired on a broad band decoupled mode. 1H NMR (400 or 
250 MHz) chemical shift values are listed in parts per million (ppm) 
downfield from TMS as the internal standard or relative to the 
corresponding non-deuterated solvent. Data are reported as follows: 
chemical shift (ppm on the δ scale), multiplicity (s = singlet, d = doublet, dd 
= doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of 
triplet, t = triplet, q = quartet and m = multiplet), coupling constant J (Hz), 
and integration. 13C NMR (101 or 63 MHz) chemical shifts are given in ppm 
relative to the corresponding non-deuterated solvent or TMS as the 
internal standard. 19F NMR (376 MHz) chemical shifts are given in ppm. 
High-resolution mass spectra were recorded with a MaXis ESI qTOF 
ultrahigh-resolution mass spectrometer (FR2708, Orléans). Melting points 
(m.p., °C) were determined using a Fisher Scientific Fisherbrand 9300 
apparatus in open capillaries and are uncorrected. Infrared spectra were 
recorded neat with a Thermo Scientific Nicolet IS10 FTIR spectrometer 
using diamond ATR golden gate sampling and are reported in wave 
numbers (cm–1). 
General Procedure for the Synthesis of Compounds 16a‒c From 
Carboxamide Derivatives 8a‒c (GP.1). A single-necked round-bottomed 
flask equipped with a magnetic stirrer and reflux condenser was charged 
with 2,2,2-trifluoroacetamide (10 equiv.) under argon atmosphere. The 
white solid was then heated at 110 °C until it melted and compound 8a‒c 
(1 equiv.) was added. The reaction mixture was heated at 160 °C for 24 h. 
Afterwards, the mixture was allowed to reach room temperature (20 °C) 
and the crude residue was purified through silica gel column 
chromatography (SiO2, CH2Cl2 : MeOH 95:5) to afford the desired product 
16a‒c in moderate to good yield. 
General Procedure for the Dehydroxychlorination of Pyrido[1,2-
e]purin-4-ol Derivatives 16a‒c (GP.2). A single-necked round-bottomed 
flask equipped with a reflux condenser under argon atmosphere was 
charged with compound 16a‒c (1 equiv.) and CHCl3 (3 mL) and the 
mixture was stirred under refluxed for 10 minutes (flask A). In parallel, a 
single-necked round-bottomed flask under argon atmosphere was 
charged with SOCl2 (5 equiv.) and anhydrous DMF (280 μL) at 0 °C (ice-
water bath) and the mixture was stirred at the same temperature for 10 
minutes (solution B). Solution B was then added to flask A, dropwise 
(syringe addition) and the reaction mixture was refluxed for 1.5 h under 
argon atmosphere. The reaction was poured into ice and water, the 
aqueous and organic layers were separated, and the organic phase was 
washed with water. The aqueous phase was then adjusted to pH 7 (sat. 
aq. NaHCO3) and extracted with Et2O. Afterwards, combined organic 
layers were dried (MgSO4), filtered through a cotton plug and evaporated 
under reduced pressure. The crude residue was purified by silica gel 
column chromatography (SiO2, CH2Cl2) to provide the desired product in 
moderate to good yield. 
General Procedure for the Suzuki-Miyaura Cross-Coupling Reactions 
of Compounds 17a‒c (GP.3). A 2-5 mL microwave vial under argon 
atmosphere was charged with a given boronic acid (1,5 equiv.), compound 
17a‒c (1 equiv.), K2CO3 (2 equiv.) and anhydrous toluene (2 mL). The 
mixture was deoxygenated by passing a stream of argon through a syringe 
and Pd(OAc)2 (0.1 equiv.) and Xantphos (0.2 equiv.) were added. The tube 
was closed with the cap and the reaction mixture was stirred at 120 °C 
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under microwave irradiation for 30 minutes. H2O (20 mL) was then added 
and the organic phase was extracted thrice with AcOEt (3 × 5 mL). Next, 
combined organic layers were dried (MgSO4), filtered through a cotton plug 
and concentrated under vacuum. The crude product was purified by 
column chromatography over silica gel. 
General Procedure for the Sonogashira Cross-coupling Reactions of 
Compounds 17a‒c (GP.4). A 2-5 mL microwave vial under argon 
atmosphere was charged with a given alkynyl derivative (1.2 equiv.), 
compound 17a‒c (1 equiv.), and 3 mL of Et3N‒anhydrous DMF (1:1, v/v). 
The mixture was deoxygenated by passing a stream of argon through a 
syringe and Pd(PPh3)2Cl2 (0.05 equiv.) and CuI (0.2 equiv.) were added. 
The tube was closed with the cap and the reaction mixture was stirred at 
70 °C under microwave irradiation for 15 minutes. H2O (20 mL) was then 
added and the organic phase was extracted thrice with AcOEt (3 × 5 mL). 
Next, combined organic layers were dried (MgSO4), filtered through a 
cotton plug and concentrated under vacuum. The crude product was 
purified by column chromatography over silica gel. 
Ethyl 3-aminoimidazo[1,2-a]pyridine-2-carboxylate (11a). A 20-mL 
microwave vial under argon atmosphere was charged with 2-
aminopyridine (200 mg, 2.12 mmol) and ethyl glyoxalate solution (50% in 
toluene) (420L, 2.12 mmol). The mixture was stirred for 2 min at rt (20 °C) 
and 1,4-Diazabicyclo[2.2.2]octane (DABCO, 238 mg, 2.12 mmol) and THF 
(4 mL) were added. The solution was then cooled to 0-5 °C (ice–water 
bath) and TMSCN (265 L, 2.12 mmol) was added dropwise. The vial was 
capped and the reaction mixture was subsequently heated under 
microwave irradiation for 15 min at 120 °C. Next, sat. aq. K2CO3 was added 
and the organic solvents were evaporated under reduced pressure (rotary 
evaporation). The aqueous phase was extracted thrice with AcOEt, 
combined organic phases dried over Na2SO4, filtered through a cotton plug 
and evaporated in vacuo. The crude titled compound was purified by 
column chromatography (SiO2, CH2Cl2:MeOH 95:5) to afford 11a as a 
yellow precipitate (261 mg, 60%). m.p.: 211-212 °C; IR (neat): ṽ = 3419, 
2084, 2987, 1677, 1638, 1573, 1268, 1183, 1026, 745, 509 cm–1; 1H NMR 
(400 MHz, DMSO-d6): δH = 8.17 (d, J = 7.1 Hz, 1 H, HAr), 7.33 (d, J = 9.3 
Hz, 1 H, HAr), 7.08 (dd, J = 9.3, 6.7, Hz, 1 H, HAr), 6.81 (t, J = 6.7 Hz, 1 H, 
HAr), 6.36 (s, 2 H, NH2), 4.27 (q, J = 7.1 Hz, 1 H, OCH2CH3), 1.31 (t, J = 
7.1 Hz, 3 H, OCH2CH3) ppm. 13C NMR (101 MHz, DMSO-d6): δC = 164.4 
(C, CO), 138.5 (C, CAr), 137.5 (C, CAr), 123.7 (CH, CHAr), 123.2 (CH, CHAr), 
118.1 (CH, CHAr), 112.6 (C, CAr), 111.5 (CH, CHAr), 59.2 (CH2, OCH2CH3), 
14.5 (CH3, OCH2CH3) ppm. 
7-Methyl-3-nitroimidazo[1,2-a]pyridine-2-carboxamide (15b). A single-
necked round-bottomed flask equipped with a reflux condenser under 
argon atmosphere, was charged with 2-Amino-4-methylpyridine (2.16 g, 
20 mmol) and EtOH absolute (50 mL) and the mixture was heated at 70 °C 
until complete dissolution. Ethyl bromopyruvate (2.76 mL, 22 mmol) was 
then added dropwise and the reaction mixture was refluxed for 5 h. After 
solvent removal (rotary evaporation), the crude material was purified 
through silica gel chromatography (SiO2, CH2Cl2:MeOH, 99:1) to afford 
ethyl 7-methylimidazo[1,2-a]pyridine-2-carboxylate 12b as a beige solid 
(2.02 g, 50%). m.p.: 133-134 °C; 1H NMR (250 MHz, CDCl3): δH = 8.09 (d, 
J = 0.8 Hz, 1 H, HAr), 7.95–7.86 (m, 1 H, HAr), 7.57 (d, J = 9.3 Hz, 1 H, HAr), 
7.08 (dd, J = 9.4, 1.7 Hz, 1 H, HAr), 4.44 (q, J = 7.1 Hz, 2 H, OCH2CH3), 
2.32 (s, 3 H, CH3), 1.50 (t, J = 7.1 Hz, 3 H, OCH2CH3) ppm. 
A round-bottomed flask under argon atmosphere was charged with 
compound 12b (3.5 g, 16.8 mmol) and the flask was cooled to 0-5 °C (ice–
water bath). Concentrated sulphuric acid (H2SO4 > 95%, 17 mL) was then 
added, followed by nitric acid (HNO3 65%, 2 mL) dropwise and the reaction 
mixture was stirred for 3 h at 0 °C. The mixture was carefully poured onto 
ice (250 g) and the yellow solid was filtered, rinsed with H2O (50 mL) and 
dried in vacuo. The crude residue was purified by column chromatography 
(SiO2, CH2Cl2) to give ethyl 7-methyl-3-nitroimidazo[1,2-a]pyridine-2-
carboxylate 14b as a yellow solid (3.4 g, 81%). m.p.: 145 °C; 1H NMR (400 
MHz, CDCl3/TMS): δH = 9.23 (d, J = 7.2 Hz, 1 H, HAr), 7.60 (br s, 1 H, HAr), 
7.17 (dd, J = 7.2, 1.7 Hz, 1 H, HAr), 4.54 (q, J = 7.2 Hz, 2 H, OCH2CH3), 
2.56 (s, 3 H, CH3), 1.45 (t, J = 7.1 Hz, 3 H, OCH2CH3). 13C NMR (101 MHz, 
CDCl3): δC = 162.1 (C, CO), 145.4 (C, CAr), 143.3 (C, CAr), 143.3 (C, CAr), 
140.8 (C, CAr), 126.6 (CH, CHAr), 120.3 (CH, CHAr), 118.0 (CH, CHAr), 63.0 
(CH2, OCH2CH3), 21.8 (CH3), 14.1 (CH3, OCH2CH3) ppm. 
Thereafter, the product (3.3 g, 13.2 mmol) was inserted in a microwave 
vial under air atmosphere and a 28-30% aq. NH4OH solution (20 ml) and 
THF (1 ml) were added. The vial was capped and the mixture was 
subsequently stirred at room temperature for 20 h. The solvents were 
evaporated under vacuum and Methanol (50 mL) was added. The 
precipitate was filtered and washed further with a mixture of methanol and 
pentane (8:2) to provide compound 15b as a yellow solid (2.61 g, 90%). 
m.p.: 295-296 °C (from MeOH); IR (neat): ṽ = 3406, 3177, 2988, 1678, 
1482, 1398, 1320, 1206, 1157, 765, 510 cm–1; 1H NMR (400 MHz, DMSO-
d6): δH = 9.22 (d, J = 7.1 Hz, 1 H, HAr), 8.08 (s, 1 H, NH), 7.90 (s, 1 H, NH), 
7.80 (s, 1 H, HAr), 7. 39 (d, J =7 .1 Hz, 1 H, HAr), 2.52 (s, 3 H, CH3) ppm; 
13C NMR (101 MHz, DMSO-d6): δC = 163.6 (C, CO), 145.2 (C, CAr), 144.9 
(C, CAr), 143.6 (C, CAr), 127.8 (C, CAr), 127.0 (CH, CHAr), 120.0 (CH, CHAr), 
116.8 (CH, CHAr), 20.9 (CH3) ppm. 
6-Methyl-3-nitroimidazo[1,2-a]pyridine-2-carboxamide (15c). A single-
necked round-bottomed flask under argon atmosphere was charged with 
2-amino-5-methylpyridine (5 g, 46 mmol) and 1,2-dimethoxyethane (DME, 
50 mL). Ethyl bromopyruvate (5.77 mL, 46 mmol) was then added, 
dropwise and the reaction mixture was stirred for 45 minutes at room 
temperature. The precipitate was filtered, washed with Et2O and dried in 
vacuo to give a yellow solid. The solid was suspended in MeOH (50 mL) 
and the suspension was heated at 90 °C until complete dissolution (1.5 h). 
The solution was concentrated and neutralized to pH 7. The mixture was 
extracted thrice with CH2Cl2, combined organic phases were dried 
(Na2SO4), filtered over a cotton plug and concentrated under vacuum. The 
residue was purified through silica gel chromatography (SiO2, CH2Cl2 : 
MeOH 95:5) to provide ethyl 6-methylimidazo[1,2-a]pyridine-2-carboxylate 
12c as a yellow light solid (5.63 g, 60%). 
Next, a round-bottomed flask under argon atmosphere was charged with 
compound 12c (4.0 g, 19.6 mmol) and the flask was cooled to 0-5 °C (ice–
water bath). Concentrated sulphuric acid (H2SO4 > 95%, 20 mL) was 
added, followed by nitric acid (HNO3 65%, 2.4 mL) dropwise and the 
reaction mixture was stirred for 3 h at 0 °C. The mixture was carefully 
poured onto ice (250 g) and the yellow solid was filtered, rinsed with H2O 
(50 mL) and dried in vacuo. The crude residue was purified by column 
chromatography (SiO2, CH2Cl2) to give ethyl 6-methyl-3-nitroimidazo[1,2-
a]pyridine-2-carboxylate 14c as a yellow solid (3.4 g, 70%). 1H NMR (400 
MHz, CDCl3): δH = 9.17 (br s, 1 H, HAr), 7.78 (d, J = 9.1 Hz, 1 H, HAr), 7.53 
(dd, J = 9.2, 1.7 Hz, 1 H, HAr), 4.55 (q, J = 7.2 Hz, 2 H, OCH2CH3), 2.52 (s, 
3 H, CH3), 1.45 (t, J = 7.1 Hz, 3 H, OCH2CH3) ppm. 13C NMR (101 MHz, 
CDCl3): δC = 162.1 (C, CO), 143.8 (C, CAr), 140.3 (C, CAr), 134.0 (C, CHAr), 
128.5 (C, CAr), 125.3 (C, CHAr), 118.6 (C, CHAr), 100.1 (C, CAr), 63.0 (CH2, 
OCH2CH3) 18.9 (CH3), 14.1 (CH3, OCH2CH3) ppm. 
Thereafter, the product (990 mg, 3.97 mmol) was inserted in a microwave 
vial under air atmosphere and 28-30% aq. NH4OH solution (4 ml) and THF 
(0.2 ml) were added. The vial was capped and the mixture was stirred at 
room temperature for 20 h. The solvents were evaporated under vacuum 
and methanol (10 mL) was added. The precipitate was filtered and washed 
further with a mixture of methanol and pentane (8:2) to afford compound 
15c as a yellow solid (800 mg, 91%). m.p.: 300 °C (from MeOH); IR (neat) 
(νmax/cm–1): 3369, 3146, 1664, 1640, 1384, 1218, 1191, 834, 799, 510; 1H 
NMR (400 MHz, DMSO-d6): δH = 9.16 (s, 1 H, HAr), 8.07 (s, 1 H, NH), 7.90 
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(s, 1 H, HAr), 7.88 (s, 1 H, NH), 7.72 (d, J = 9.0 Hz, 1 H, HAr), 2.47 (s, 3 H, 
CH3) ppm; 13C NMR (101 MHz, DMSO-d6): δC = 163.6 (C, CO), 144.7 (C, 
CAr), 143.4 (C, CAr), 134.5 (C, CHAr), 127.8 (C, CAr), 125.4 (C, CHAr), 117.5 
(C, CHAr), 17.9 (CH3) ppm. 
Aminoimidazo[1,2-a]pyridine-2-carboxamide (8a). A microwave vial 
under air atmosphere was charged with imidazo[1,2-a]pyridine 11a (550 
mg, 2.44 mmol), 28-30% aq. NH4OH solution (10 ml) and THF (0.5 ml). 
The vial was sealed and the mixture was stirred at 70 °C for 48 h (normal 
heating with an oil bath). The solvents were evaporated under vacuum and 
the residue was purified through neutral alumina column (Al2O3, CH2Cl2 : 
MeOH 9:1) to furnish compound 8a as a yellow solid (342 mg, 81%). m.p.: 
233-236 °C; IR (neat): ṽ = 3381, 3309, 3108, 1660, 1600, 1498, 1323, 
1246, 698, 617, 510 cm–1; 1H NMR (400 MHz, DMSO-d6): δH = 8.13 (d, J 
= 7.0 Hz, 1 H, HAr), 7.40 (br s, 1 H, NH), 7.34 (d, J = 9.3 Hz, 1 H, HAr), 7.14 
(br s, 1 H, NH), 7.06 (dd, J = 12.3, 1.2 Hz, 1 H, HAr), 6.80 (t, J = 6.7 Hz, 1 
H, HAr), 6.14 (s, 2 H, HAr) ppm; 13C NMR (101 MHz, DMSO-d6): δC = 167.1 
(C, CO), 136.7 (C, CAr), 135.4 (C, CAr), 123.1 (C, CHAr), 123.0 (C, CHAr), 
117.5 (C, CHAr), 116.2 (C, CAr), 111.3 (C, CHAr) ppm. 
3-Amino-7-methylimidazo[1,2-a]pyridine-2-carboxamide (8b). A 
single-necked round-bottomed flask under air atmosphere was charged 
with carboxamide 15b (500 mg, 2.27 mmol), 10% Pd/C and EtOH (≥95%). 
The suspension was degassed under vacuum and the flask was filled with 
H2 (H2-filled balloon) five times. The reaction mixture was stirred at 20 °C 
under hydrogen atmosphere (balloon of H2) for 14 h. Next, the mixture was 
filtered through celite and the filter residue was rinsed with MeOH. The 
solvents were evaporated (rotary evaporation) and the residue was 
purified by column chromatography (SiO2, CH2Cl2 : MeOH 95:5) to provide 
the titled compound as an off white precipitate (302 mg, 70%). m.p. > 
260 °C; IR (neat): ṽ = 3674, 3390, 3270, 3106, 1656, 1614, 1456, 1409, 
1245, 1066, 775, 521 cm–1; 1H NMR (400 MHz, DMSO-d6): δH = 8.04 (d, J 
= 7.1 Hz, 1 H, HAr), 7.27 (br s, 1 H, NH), 7.11 (s, 1 H, HAr), 7.04 (br s, 1 H, 
NH), 6.67 (d, J = 7.1 Hz, 1 H, HAr), 6.06 (s, 2 H, NH2), 2.31 (s, 3 H, CH3) 
ppm; 13C NMR (101 MHz, DMSO-d6): δC = 167.1 (C, CO), 137.0 (C, CAr), 
135.1 (C, CAr), 133.4 (C, CAr), 122.2 (CH, CHAr), 115.8 (C, CAr), 115.3 (CH, 
CHAr), 113.9 (CH, CHAr), 20.9 (CH3) ppm. 
3-Amino-6-methylimidazo[1,2-a]pyridine-2-carboxamide (8c). A 
microwave vial under argon atmosphere was charged with carboxamide 
15c (700 mg, 3.18 mmol), Tin (II) chloride dihydrate (3.56 g, 15.8 mmol) 
and EtOH (≥95%; 15 mL). The vial was sealed and the reaction mixture 
was heated under microwave irradiation at 100 °C for 10 min. After 
solvents removal (rotary evaporation) the crude residue was then diluted 
with EtOAc (50 mL) and the organic phase was washed successively with 
NaHCO3 (20 mL) and brine (30 mL). Next, the organic layer was dried 
(MgSO4), filtered through a cotton plug and evaporated under reduced 
pressure. The crude product was purifed by column chromatography over 
silica gel (CH2Cl2 : MeOH 95:5) to give 8c as a beige solid (452 mg, 75%). 
m.p.: 250-252 °C; IR (neat): ṽ = 3674, 3390, 3270, 3106, 2987, 1656, 1614, 
1409, 1305, 1245, 1066, 1014, 775, 706, 603 cm–1; 1H NMR (250 MHz, 
DMSO-d6): δH = 7.93 (s, 1 H, HAr), 7.26 (d, 2 H, J = 9.3 Hz, HAr + NH), 7.05 
(br s, 1 H, NH), 6.92 (dd, J = 9.4, 1.5 Hz, 1 H, HAr), 6.04 (s, 2 H, NH2), 2.23 
(s, 3 H, CH3) ppm.13C NMR (63 MHz, DMSO-d6) δC = 167.0 (C, CO), 135.9 
(C, CAr), 135.0 (C, CAr), 126.3 (C, CHAr), 120.3 (C, CAr), 120.0 (CH, CHAr), 
116.9 (CH, CHAr), 116.4 (CH, CHAr), 17.8 (CH3) ppm. 
2-(Trifluoromethyl)pyrido[1,2-e]purin-4-ol (16a). According to GP1, the 
reaction was performed with carboxamide 8a (200 mg, 1.13 mmol) and 
CF3(CO)NH2 (1.28 g, 11.35 mmol) to furnish compound 17a as a white 
solid (201 mg, 70%). m.p.: 310-312 °C; IR (neat): ṽ = 3231, 2987, 2900, 
1641, 1599, 1478, 1349, 1259, 1127, 755, 514 cm–1; 1H NMR (400 MHz, 
Methanol-d4): δH = 8.63 (d, J = 6.8 Hz, 1 H, HAr) ,7.62 (d, J = 9.3 Hz, 1 H, 
HAr), 7.51 (dd, J = 6.8, 9.3 Hz, 1 H, HAr), 7.02 (t, J = 6.8 Hz, 1 H, HAr) ppm; 
13C NMR (101 MHz, Methanol-d4): δC = 169.0 (C, CO), 150.3 (q = 34.6 Hz, 
C‒CF3), 147.0 (C, CAr), 144.3 (C, CAr), 131.8 (CH, CHAr), 127.5 (C, CAr), 
125.9 (CH, CHAr), 124.2 (q, J = 274.3 Hz, CF3), 118.8 (CH, CHAr), 113.9 
(CH, CHAr) ppm; 19F NMR (376 MHz, Methanol-d4): δF = ‒70.7 ppm; HRMS 
(ESI): m/z calcd. for C10H6F3N4O [M + H]+ 255.0488; found 255.0488. 
7-Methyl-2-(trifluoromethyl)pyrido[1,2-e]purin-4-ol (16b). According to 
GP1, the reaction was performed with carboxamide 8b (300 mg, 1.58 
mmol) and CF3(CO)NH2 (1.78 g, 15.8 mmol) to furnish compound 16b as 
a white solid (310 mg, 73%). m.p.: 253-255 °C; IR (neat): ṽ = 3674, 2987, 
1693, 1477, 1358, 1286, 1202, 1132, 997, 784 cm–1; 1H NMR (250 MHz, 
Methanol-d4): δH = 8.52 (d, J = 7.1 Hz, 1 H, HAr), 7.37 (s, 1 H, HAr), 6.91 
(dd, J = 7.1, 1.5 Hz, 1 H, HAr), 2.43 (s, 3 H, CH3) ppm; 19F NMR (376 MHz, 
Methanol-d4): δF = ‒70.5 ppm; HRMS (ESI): m/z calcd. for C11H8F3N4O [M 
+ H]+ 269.0645; found 269.0647. 
8-Methyl-2-(trifluoromethyl)pyrido[1,2-e]purin-4-ol (16c). According to 
GP1, the reaction was performed with carboxamide 8c (150 mg, 0.79 
mmol) and CF3(CO)NH2 (1.78 g, 7.9 mmol) to give compound 16c as a 
white solid (122 mg, 58%). m.p.: 250-252 °C; IR (neat): ṽ = 3674, 2987, 
1651, 1601, 1478, 1384, 1262, 1131, 995, 806 cm–1; 1H NMR (400 MHz, 
Methanol-d4): δH = 8.44 (s, 1 H, HAr), 7.52 (d, J = 9.4 Hz, 1 H, HAr), 7.39 (d, 
J = 9.4 Hz, 1 H, HAr), 2.39 (s, 3 H, CH3) ppm; 19F NMR (376 MHz, Methanol-
d4): δF = ‒70.6 ppm; HRMS (ESI): m/z calcd. for C11H8F3N4O [M + H]+ 
269.0645; found 269.0648. 
4-Chloro-2-(trifluoromethyl)pyrido[1,2-e]purine (17a). According to 
GP2, the reaction was accomplished with purine 16a (150 mg, 0.59 mmol) 
and SOCl2 (214 μL, 2.95 mmol) to give compound 17a as a white solid 
(124 mg, 77%). m.p.: 210-211°C; IR (neat): ṽ = 3113, 3035, 1646, 1397, 
1300, 1125, 911, 758 cm–1; 1H NMR (250 MHz, CDCl3): δH = 8.86 (dd, J = 
6.8, 1.0 Hz, 1 H, HAr), 7.88 (d, J = 6.8 Hz, 1 H, HAr), 7.76 (td, J = 6.8, 1.0 
Hz, 1 H, HAr), 7.18 (td, J = 6.8, 1.0 Hz, 1 H, HAr) ppm; 13C NMR (63 MHz, 
CDCl3): δC = 151.7 (C, CAr), 150.9 (C, CAr), 146.8 (q, J = 38.1 Hz, C‒CF3), 
146.0 (C, CAr), 134.6 (CH, CHAr), 134.0 (C, CAr), 125.7 (CH, CHAr), 119.7 
(q, J = 274.1 Hz, CF3), 119.4 (CH, CHAr), 113.8 (CH, CHAr) ppm; 19F NMR 
(376 MHz, CDCl3): δF = ‒68.0 ppm; HRMS (ESI): m/z calcd. for 
C10H5ClF3N4 [M + H]+ 273.0149; found 273.014. 
4-Chloro-7-methyl-2-(trifluoromethyl)pyrido[1,2-e]purine (17b). 
According to GP2, the reaction was accomplished with purine 16b (220 
mg, 0.82 mmol) and SOCl2 (298 μL, 4.10 mmol) to give compound 17b as 
a beige solid (141 mg, 60%). m.p.: 220-222 °C; IR (neat): ṽ = 3051, 2928, 
1650, 1555, 1497, 1356, 1435, 1374, 1257, 1199, 1130, 943, 890, 703 cm–
1; 1H NMR (400 MHz, CDCl3): δH = 8.71 (d, J = 7.1 Hz, 1 H, HAr), 7.60 (d, 
J = 1.8 Hz, 1 H, HAr), 7.00 (dd, J = 7.1, 1.8 Hz, 1 H, HAr), 2.58 (s, 3 H, CH3) 
ppm; 13C NMR (101 MHz, CDCl3) δC = 151.4 (C, CAr), 150.8 (C, CAr), 147.1 
(C, CAr), 146.4 (q, J = 36.6 Hz, C‒CF3), 146.3 (C, CAr), 134.3 (C, CAr), 124.6 
(CH, CHAr), 119.7 (q, J = 274.1 Hz, CF3), 117.2(CH, CHAr), 116.8 (CH, 
CHAr), 22.6 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δF = ‒68.0 ppm; 
HRMS (ESI): m/z calcd. for C11H7ClF3N4 287.0306; found 287.0303. 
4-Chloro-8-methyl-2-(trifluoromethyl)pyrido[1,2-e]purine 17c. 
According to GP2, the reaction was accomplished with purine 16c (140 
mg, 0.52 mmol) and SOCl2 (190 μL, 2.6 mmol) to give compound 17c as 
a beige solid (97 mg, 65%). m.p.: 196-198 °C; IR (neat): ṽ = 3052, 2929, 
1651, 1556, 1498, 1357, 1436, 1375, 1256, 1198, 1129, 1063, 943, 890, 
794, 702 cm–1; 1H NMR (250 MHz, CDCl3): δH = 8.70‒8.60 (m, 1 H, HAr), 
7.79 (dd, J = 9.5, 1.2 Hz, 1 H, HAr), 7.62 (dd, J = 9.5, 1.8 Hz, 1 H, HAr), 2.50 
(d, J = 1.2 Hz, 3 H, CH3) ppm; 13C NMR (63 MHz, CDCl3): δC = 151.4 (C, 
CAr), 150.2 (C, CAr), 146.5 (q, J = 38.5 Hz, C‒CF3), 145.8 (C, CAr), 138.1 
(CH, CHAr), 134.0 (C, CAr), 124.1 (C, CAr), 122.8 (CH, CHAr), 119.7 (q, J = 
276.8 Hz, CF3), 118.6 (CH, CHAr), 18.3 (CH3) ppm; 19F NMR (376 MHz, 
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CDCl3): δF = ‒68.0; HRMS (ESI): m/z calcd. for C11H7ClF3N4 287.0306; 
found 287.0306. 
4-(p-Tolyl)-2-(trifluoromethyl)pyrido[1,2-e]purine (18a). According to 
GP3, the reaction was performed with compound 17a (50 mg, 183 μmol) 
and p-tolylboronic acid. The crude product was purified by column 
chromatography (SiO2, petroleum ether : EtOAc 7:3) to give compound 18 
as a yellow solid (51 mg, 85%). m.p.: 195-197 °C; IR (neat): ṽ = 2918, 
2854, 1637, 1574, 1396, 1264, 1178, 1127, 1049, 890, 764, 717, 510 cm–
1; 1H NMR (400 MHz, CDCl3): δH = 8.96 (d, J = 8.1 Hz, 2 H, HAr tol), 8.86 
(d, J = 6.8 Hz, 1 H, HAr), 7.85 (d, J = 9.3 Hz, 1 H, HAr), 7.67 (ddd, J = 9.3, 
6.8, 1.3 Hz, 1 H, HAr), 7.42 (d, J = 8.1 Hz, 2 H, HAr tol), 7.06 (t, J = 6.8 Hz, 
1 H, HAr), 2.48 (s, 3 H, CH3) ppm; 13C NMR (101 MHz, CDCl3): δC = 155.7 
(C, CAr), 150.2 (C, CAr), 147.3 (C, CAr), 147.4 (q, J = 36.8 Hz, C‒CF3), 142.6 
(C, CAr), 133.4 (C, CHAr), 133.0 (C, CAr), 132.6 (C, CAr), 130.5 (2 × CH, 
CHAr tol), 129.8 (2 × CH, CHAr tol), 125.4 (CH, CHAr), 120.5 (q, J = 274.8 
Hz, CF3), 119.2 (CH, CHAr), 112.7 (CH, CHAr), 21.9 (CH3) ppm; 19F NMR 
(376 MHz, CDCl3): δF = ‒68.2 ppm; HRMS (ESI): m/z calcd. for C17H12F3N4 
[M+H]+ 329.1009; found 329.1010. 
4-(4-Methoxyphenyl)-2-(trifluoromethyl)pyrido[1,2-e]purine (21a). 
According to GP3, the reaction was performed with compound 17a (50 mg, 
183 μmol) and 4-methoxyphenylboronic acid. The crude product was 
purified by column chromatography (SiO2, petroleum ether : EtOAc 7:3) to 
give compound 21a as a yellow solid (43 mg, 69%). m.p.: 216-217 °C; IR 
(neat): ṽ = 2969, 1640, 1568, 1514, 1403, 1306, 1174, 1050, 715, 601 cm–
1; 1H NMR (400 MHz, CDCl3): δH = 9.08 (d, J = 8.6 Hz, 2 H, HAr tol), 8.84 
(d, J = 6.8 Hz, 1 H, HAr), 7.82 (d, J = 9.3 Hz, 1 H, HAr), 7.66 (t, J = 6.8 Hz, 
1 H, HAr), 7.13 (d, J = 8.6 Hz, 2 H, HAr tol), 7.06 (t, J = 6.8 Hz, 1 H, HAr), 
3.93 (s, 3 H, OCH3); 13C NMR (101 MHz, CDCl3): δC = 162.9 (C, CO), 
155.3 (C, CAr), 149.9 (C, CAr), 147.4 (q, J = 36.8 Hz, C‒CF3), 147.0 (C, 
CAr), 133.3 (CH, CHAr), 132.6 (C, CAr), 132.4 (2 × CH, CHAr anis), 128.1 (C, 
CAr), 125.4 (CH, CHAr), 119.5 (q, J = 276.6 Hz, CF3), 119.1 (CH, CHAr), 
114.4 (2 × CH, CHAr anis), 112.7 (CH, CHAr), 55.6 (CH3, OCH3) ppm; 19F 
NMR (376 MHz, CDCl3): δF = ‒68.3 ppm; HRMS (ESI) m/z calcd. for 
C17H12F3N4O [M+H]+ 345,0958; found 345,0964. 
4-(4-Trifluoromethoxyphenyl)-2-(trifluoromethyl)pyrido[1,2-e]purine 
(22a). According to GP3, the reaction was accomplished with compound 
17a (50 mg, 183 μmol) and 4-(trifluoromethoxy)phenylboronic acid. The 
crude product was purified by column chromatography (SiO2, CH2Cl2 : 
petroleum ether 5:5) to give the titled compound as a yellow solid (53 mg, 
73%). m.p.: 126-128 °C; IR (neat): ṽ = 2918, 1641, 1582, 1510, 1386, 1343, 
1248, 1050, 1019, 759, 717, 503, 643 cm–1; 1H NMR (400 MHz, CDCl3): 
δH = 9.10 (d, J = 8.7 Hz, 2 H, HAr), 8.84 (d, J = 6.8 Hz, 1 H, HAr), 7.80 (d, J 
= 9.3 Hz, 1 H, HAr), 7.69 (t, J = 6.8 Hz, 1 H, HAr), 7.43 (d, J = 8.4 Hz, 2 H, 
HAr), 7.09 (t, J = 6.8 Hz, 1 H, HAr) ppm; 13 C NMR (101 MHz, CDCl3): δC = 
153.7 (C, CAr), 151.9 (q, J = 1.8 Hz, C‒OCF3), 150.5 (C, CAr), 147.5 (C, 
CAr), 147.3 (q, J = 37.2 Hz, C‒CF3), 133.9 (CH, CHAr), 133.7 (C, CAr), 133.0 
(C, CAr), 132.2 (2 × CH, CHAr), 125.4 (CH, CHAr), 120.9 (CH, CHAr), 120.6 
(q, J = 258.2 Hz, OCF3), 120.4 (q, J = 274.6 Hz, C, CF3), 119.1 (CH, CHAr), 
113.0 (CH, CHAr) ppm; 19F NMR (376 MHz, CDCl3) δF = ‒57.5, ‒68.2 ppm; 
HRMS (ESI): m/z calcd. for C17H9F6N4O [M+H]+ 399.0675; found 399.0673. 
4-(4-Trifluoromethylphenyl)-2-(trifluoromethyl)pyrido[1,2-e]purine 
(23a). According to GP3, the reaction was accomplished with compound 
17a (50 mg, 183 μmol) and 4-(trifluoromethyl)phenylboronic acid. The 
crude product was purified by column chromatography (SiO2, CH2Cl2 : 
petroleum ether 6:4) to give compound 23a as a yellow solid (56 mg, 80%). 
m.p.: 164-165 °C; IR (neat): ṽ = 2920, 1638, 1558, 1486, 1420, 1268, 1304, 
1214, 1196, 1068, 1047, 891, 807, 719, 653 cm–1; 1H NMR (400 MHz, 
CDCl3): δH = 9.15 (d, J = 8.1 Hz, 2 H, HAr), 8.86 (d, J = 6.8 Hz, 1 H, HAr), 
7.84 (t, J = 8.1 Hz, 2 H, HAr), 7.72 (dd, J = 9.4, 6.6 Hz, 1 H, HAr), 7.11 (t, J 
= 6.8 Hz, 1 H, HAr) ppm; 13 C NMR (101 MHz, CDCl3): δC = 153.4 (C, CAr), 
150.8 (C, CAr), 147.8 (C, CAr), 147.2 (q, J = 37.2 Hz, C‒CF3), 138.4 (q, J = 
1.6 Hz, C, CAr), 134.2 (CH, CHAr), 133.4 (C, CAr), 133.1 (q, J = 32.6 Hz, C‒
CF3), 130.6 (2 × CH, CHAr), 125.8 (q, J = 3.74 Hz, 2 × CH, CHAr), 125.5 
(CH, CHAr), 124.1 (q, J = 272.5 Hz, CF3), 120.4 (q, J = 274.6 Hz, CF3), 
119.2 (CH, CHAr), 113.1 (CH, CHAr) ppm;19F NMR (376 MHz, CDCl3): δF = 
‒63.0, ‒68.2 ppm; HRMS (ESI): m/z calcd. for C17H9F6N4 [M+H]+ 
383.0726; found 383.0726. 
4-(3-(Trifluoromethylphenyl)-2-(trifluoromethyl)pyrido[1,2-e]purine 
(25a). According to GP3, the reaction was carried out with compound 17a 
(50 mg, 183 μmol) and 3-(trifluoromethyl)phenylboronic acid. The crude 
product was purified by column chromatography (SiO2, petroleum ether : 
EtOAc 5:5) to give compound 25a as a yellow solid (54mg, 78%). m.p.: 
143-144 °C; IR (neat): ṽ = 2921, 1642, 1581, 1498, 1260, 1094, 1075, 904, 
759 cm–1; 1H NMR (400 MHz, CDCl3): δH = 9.34 (s, 1 H, HAr), 9.29 (d, J = 
7.9 Hz, 1 H, HAr), 8.86 (dd, J = 6.8, 1.2 Hz, 1 H, HAr), 7.90-7.78 (m, 2 H, 
HAr), 7.78-7.65 (m, 2 H, HAr), 7.11 (t, J = 6.8 Hz, 1 H, HAr) ppm; 13 C NMR 
(101 MHz, CDCl3): δC = 154.0 (C, CAr), 150.7 (C, CAr), 147.7 (C, CAr), 147.2 
(q, J = 37.3 Hz, C‒CF3), 136.0 (C, CAr), 134.1 (CH, CHAr), 133.6 (CH, CHAr), 
133.2 (C, CAr), 131.4 (q, J = 32.5 Hz, C‒CF3), 129.5 (CH, CHAr), 128.2 (q, 
J = 3.6 Hz, CH, CHAr), 127.1 (q, J = 4.0 Hz, CH, CHAr), 125.5 (CH, CHAr), 
124.3 (q, J = 272.4 Hz, CF3), 120.9 (q, J = 258.4 Hz, CF3), 119.2 (CH, 
CHAr), 113.1 (CH, CHAr) ppm; 19F NMR (376 MHz, CDCl3): δF = ‒62.6, ‒
68.1 ppm; HRMS (ESI): m/z calcd. for C17H9F6N4 [M+H]+ 383.0726; found 
383.0726. 
4-(3-Methylphenyl)-2-(trifluoromethyl)pyrido[1,2-e]purine (20a). 
According to GP3, the reaction was achieved with compound 17a (40 mg, 
147 μmol) and 3-methoxyphenylboronic acid. The crude product was 
purified by column chromatography (SiO2, petroleum ether : EtOAc 7:3) to 
give compound 20a as a yellow solid (39 mg, 65%). m.p.: 192-193 °C; IR 
(neat): ṽ = 2923, 1639, 1573, 1392, 1273, 1221, 1179, 1142, 1054, 924, 
793, 754, 649, 624 cm–1; 1H NMR (250 MHz, CDCl3): δH = 8.94‒8.72 (m, 
3 H, HAr), 7.83 (d, J = 9.4 Hz, 1 H, HAr), 7.66 (ddd, J = 9.4, 6.8, 1.4 Hz, 1 
H, HAr), 7.51 (t, J = 7.6 Hz, 1 H, HAr), 7.39 (d, J = 7.6 Hz, 1 H, HAr), 7.06 
(td, J = 6.8, 1.1 Hz, 1 H, HAr), 2.54 (s, 3 H, CH3) ppm; 13C NMR (63 MHz, 
CDCl3): δC = 155.8 (C, CAr), 150.2 (C, CAr), 147.5 (C, CAr), 147.3 (q, J = 
37.0 Hz, C‒CF3), 138.7 (C, CAr), 135.2 (C, CAr), 133.5 (CH, CHAr), 133.1 
(C, CAr), 132.8 (CH, CHAr), 130.6 (CH, CHAr), 128.9 (CH, CHAr), 127.9 (CH, 
CHAr), 125.4 (CH, CHAr), 120.5 (q, J = 274.6 Hz, CF3), 119.2 (CH, CHAr), 
112.8 (CH, CHAr), 21.8 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δF = ‒68.0 
ppm; HRMS (ESI): m/z calcd. for C17H12F3N4 [M+H]+ 329.1008; found 
329.1009. 
2-(Trifluoromethyl)-4-(2-(trifluoromethyl)phenyl)pyrido[1,2-e]purine 
(24a). According to GP3, the reaction was performed with compound 17a 
(50 mg, 183 μmol) and 2-(trifluoromethyl)phenylboronic acid. The crude 
product was purified by column chromatography (SiO2, CH2Cl2) to give 
compound 24a as a yellow solid (52.5 mg, 75%). m.p.: 115-116 °C; IR 
(neat): ṽ = 2919, 2850, 1640, 1588, 1506, 1400, 1346, 1302,1126, 1067, 
908, 759, 657, 525 cm–1; 1H NMR (250 MHz, CDCl3): δH = 8.92 (d, J = 6.9, 
1.3 Hz, 1 H, HAr), 7.92 (br d, J = 6.9 Hz, 2 H, HAr), 7.80‒7.60 (m, 4 H, HAr), 
7.13 (t, J = 6.7, 1.2 Hz, 1 H, HAr) ppm; 13C NMR (63 MHz, CDCl3): δC = 
157.4 (C, CAr), 151.0 (C, CAr), 146.9 (q, J = 37.4 Hz, C‒CF3), 146.9 (C, 
CAr), 134.2 (CH, CHAr), 133.7‒133.5 (m, C, CAr), 132.2 (CH, CHAr), 131.8 
(CH, CHAr), 130.3 (CH, CHAr), 129.7 (q, J = 31.8 Hz, C‒CF3), 127.7 (q, J = 
5.0 Hz, CH, CHAr), 125.6 (CH, CHAr), 123.9 (q, J = 274.0 Hz, CF3), 120.3 
(q, J = 272.5 Hz, CF3), 119.3 (CH, CHAr), 113.1 (C, CHAr) ppm; 19F NMR 
(376 MHz, CDCl3): δF = ‒57.2, ‒68.1 ppm; HRMS (ESI): m/z calcd. for 
C17H9F6N4 [M+H]+ 383.0726; found 383.0726. 
4-Phenyl-2-(trifluoromethyl)pyrido[1,2-e]purine (19a). According to 
GP3, the reaction was performed with compound 17a (50 mg, 183 μmol) 
and phenylboronic acid. The crude product was purified by column 
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chromatography (SiO2, petroleum ether : EtOAc 7:3) to give compound 
19a as a yellow solid (42 mg, 74%). m.p.: 191-192 °C; IR (neat): ṽ = 2987, 
1639, 1570, 1398, 1346, 1247, 11156, 1050, 908, 755, 717 cm–1; 1H NMR 
(400 MHz, CDCl3): δH = 9.04 (d, J = 7.8 Hz, 2 H, HAr), 8.86 (d, J = 6.8 Hz, 
1 H, HAr), 7.84 (d, J = 9.3 Hz, 1 H, HAr), 7.68 (dd, J = 9.3, 6.8 Hz,1 H, HAr), 
7.61 (q, J = 9.5, 8.1 Hz, 3 H, HAr), 7.07 (t, J = 6.8 Hz, 1 H, HAr) ppm; 13C 
NMR (101 MHz, CDCl3): δC = 155.6 (C, CAr), 150.4 (C, CAr), 147.4 (C, CAr), 
147.4 (q, J = 37.1 Hz, C‒CF3), 135.3 (C, CAr), 133.7 (CH, CHAr), 133.2 (C, 
CAr), 131.9 (CH, CHAr), 130.5 (2 × CH, CHAr), 129.0 (2 × CH, CHAr), 125.4 
(CH, CHAr), 120.5 (q, J = 274.7 Hz, CF3), 119.2 (CH, CHAr), 112.8 (CH, 
CHAr) ppm; 19F NMR (376 MHz, CDCl3): δF = ‒68.2 ppm; HRMS (ESI): m/z 
calcd. for C16H10F3N4 [M+H]+ 315,0852; found 315.0855. 
4-(Naphthalen-1-yl)-2-(trifluoromethyl)pyrido[1,2-e]purine (26a). 
According to GP3, the reaction was accomplished with compound 17a (50 
mg, 183 μmol) and naphthalenyl-1-boronic acid. The crude product was 
purified by column chromatography (SiO2, petroleum ether : EtOAc 7:3) to 
give compound 26a as a yellow solid (45 mg, 70%). m.p.: 216-218 °C; IR 
(neat): ṽ = 3106, 2209, 1637, 1574, 1287, 1120, 1128, 954, 755, 686, 598 
cm–1; 1H NMR (400 MHz, CDCl3): δH = 8.92 (d, J = 6.9 Hz, 1 H, HAr), 8.48-
8.40 (m, 1 H, HAr), 8.33 (dd, J = 7.2, 1.3 Hz, 1 H, HAr), 8.06 (d, J = 8.2 Hz, 
1 H, HAr), 7.99-7.90 (m, 1 H, HAr), 7.80 (d, J = 9.4 Hz, 1H, HAr), 7.74-7.63 
(m, 2 H, HAr), 7.61-7.48 (m, 2 H, HAr), 7.10 (t, J = 6.7 Hz, 1 H, HAr) ppm; 
13C NMR (101 MHz, CDCl3) δC = 159.0 (C, CAr), 150.6 (C, CAr), 147.2 (q, 
J = 37.1 Hz, C‒CF3), 147.0 (C, CAr), 134.7 (C, CAr), 134.4 (C, CAr), 133.8 
(CH, CHAr), 131.7 (C, CAr), 131.7 (CH, CHAr), 131.2 (C, CAr), 131.2 (CH, 
CHAr), 128.7 (CH, CHAr), 127.3 (CH, CHAr), 126.4 (CH, CHAr), 125.7 (CH, 
CHAr), 125.5 (CH, CHAr), 125.3 (CH, CHAr), 120,5 (q, J = 274.7 Hz, CF3), 
119.3 (CH, CHAr), 113.0 (CH, CHAr) ppm;  19F NMR (376 MHz, CDCl3): δF 
= ‒67.9 ppm; HRMS (ESI): m/z calcd. for C20H11F3N4 [M+H]+ 365,0952; 
found 355.0955. 
7-Methyl-4-(p-tolyl)-2-(trifluoromethyl)pyrido[1,2-e]purine (18b). 
According to GP3, the reaction was carried out with compound 17b (52 
mg, 183 μmol) and p-tolylboronic acid. The crude product was purified by 
column chromatography (SiO2, petroleum ether : EtOAc 8:2) to give 
compound 18b as a yellow solid (50 mg, 80%). m.p.: 237-239 °C; IR (neat): 
ṽ = 2923, 1647, 1568, 1513, 1298, 1204, 1047, 897, 788 cm–1; 1H NMR 
(400 MHz, CDCl3): δH = 8.91 (d, J = 8.0 Hz, 2 H, HAr tol), 8.65 (d, J = 7.0 
Hz, 1 H, HAr), 7.51 (s, 1 H, HAr), 7.40 (d, J = 8.0 Hz, 2 H, HAr tol), 6.83 (dd, 
J = 7.0, 1.6 Hz, 1 H, HAr), 2.51 (s, 3 H, CH3), 2.48 (s, 3 H, CH3) ppm; 13C 
NMR (101 MHz, CDCl3): δC = 154.8 (C, CAr), 150.6 (C, CAr), 147.3 (C, 
CAr),146.8 (q, J = 36.9 Hz, C‒CF3), 145.5 (C, CAr), 142.3 (C, CAr), 133.1 
(C, CAr), 132.7 (C, CAr), 130.3 (2 × CH, CHAr tol), 129.7 (2 × CH, CHAr tol), 
124.2 (CH, CHAr), 120.6 (q, J = 274.5 Hz, CF3), 116.9 (CH, CHAr), 115.6 
(CH, CHAr), 22.4 (CH3), 21.9 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δF = 
‒68.1 ppm; HRMS (ESI): m/z calcd. for C18H14F3N4 [M+H]+ 343.1165; 
found 343.1165. 
8-Methyl-4-(p-tolyl)-2-(trifluoromethyl)pyrido[1,2-e]purine (18c). 
According to GP3, the reaction was accomplished with compound 17c (20 
mg, 70 μmol) and p-tolylboronic acid. The crude product was purified by 
column chromatography (SiO2, petroleum ether : EtOAc 8:2) to give 
compound 18c as a yellow solid (19 mg, 78%). m.p.: 234-236 °C; IR (neat): 
ṽ = 2920, 1640, 1570, 1516, 1299, 1200, 1048, 890, 784 cm–1;  1H NMR 
(400 MHz, CDCl3): δH = 8.93 (d, J = 8.2 Hz, 2 H, HAr tol), 8.62 (s, 1 H, HAr), 
7.73 (d, J = 9.5 Hz, 1 H, HAr), 7.50 (dd, J = 9.5, 1.8 Hz, 1 H, HAr), 7.41 (d, 
J = 8.2 Hz, 2 H, HAr tol), 2.48 (s, 3 H, CH3), 2.45 (d, J = 1.4 Hz, 3 H, CH3) 
ppm; 13C NMR (101 MHz, CDCl3): δC = 155.4 (C, CAr), 149.4 (C, CAr), 146.9 
(C, CAr), 146.5 (q, J = 37.2 Hz, C‒CF3), 142.4 (C, CAr), 136.9 (CH, CHAr), 
133.0 (C, CAr), 132.7 (C, CAr), 130.4 (2 × CH, CHAr tol), 129.7 (2 × CH, 
CHAr tol), 122.8 (C, CAr), 122.5 (CH, CHAr), 120.6 (q, J = 274.7 Hz, CF3), 
118.3 (CH, CHAr), 21.9 (CH3), 18.2 (CH3) ppm; 19F NMR (376 MHz, CDCl3): 
δF = ‒68.2 ppm; HRMS (ESI): m/z calcd. for C18H14F3N4 [M+H]+ 343.1165; 
found 343.1165. 
7-Methyl-4-(4-(trifluoromethoxy)phenyl)-2(trifluoromethyl) 
pyrido[1,2-e]purine (22b). According to GP3, the reaction was 
accomplished with compound 17b (52 mg, 183 μmol) and 4-
(trifluoromethoxy)phenylboronic acid. The crude product was purified by 
column chromatography (SiO2, petroleum ether : EtOAc 7:3) to give 
compound 22b as a yellow solid (52 mg, 70%). m.p.: 149-150 °C; IR (neat): 
ṽ = 2917, 1651, 1402, 1252, 1140, 1049, 1018, 673, 629, 509 cm–1; 1H 
NMR (400 MHz, CDCl3): δH = 9.06 (d, J = 8.9 Hz, 2 H, HAr), 8.66 (d, J = 
7.1 Hz, 1 H, HAr), 7.50 (s, 1 H, HAr), 7.42 (br d, J = 8.9 Hz, 2 H, HAr), 6.87 
(br d, J = 7.1 Hz, 1 H, HAr), 2.52 (s, 3 H, CH3) ppm; 13C NMR (101 MHz, 
CDCl3): δC = 152.9 (C, CAr), 151.7 (q, J = 1.8 Hz, C‒OCF3), 151.0 (C, CAr), 
147.6 (C, CAr), 146.7 (q, J = 37.2 Hz, C‒CF3), 146.2 (C, CAr), 133.8 (C, 
CAr), 133.3 (C, CAr), 132.1 (2 × CH, CHAr), 124.5 (CH, CHAr), 120.8 (CH, 
CHAr), 120.6 (q, J = 258.2 Hz, OCF3), 120.4 (q, J = 274.5 Hz, CF3), 116.9 
(CH, CHAr), 115.9 (CH, CHAr), 22.5 (CH3) ppm; 19F NMR (376 MHz, 
CDCl3): δF = ‒57.5, ‒68.2 ppm; HRMS (ESI): m/z calcd. for C18H11F6N4O 
[M+H]+ 413.0832; found 413.0829. 
8-Methyl-4-(4-(trifluoromethoxy)phenyl)-2-
(trifluoromethyl)pyrido[1,2-e]purine (22c). According to GP3, the 
reaction was carried out with compound 17c (20 mg, 69 μmol) and 4-
(trifluoromethoxy)phenylboronic acid. The crude product was purified by 
column chromatography (SiO2, petroleum ether : EtOAc 8:2) to give 
compound 22c as a yellow solid (20 mg, 70%). m.p.: 139-140 °C; IR (neat): 
ṽ = 2918, 2649, 1652, 1577, 1422, 1197, 1046, 937, 852, 708 cm–1; 1H 
NMR (400 MHz, CDCl3): δH = 9.13-9.08 (m, 2 H, HAr), 8.68-8.65 (m, 1 H, 
HAr), 7.75 (d, J = 9.4 Hz, 1 H, HAr), 7.56 (dd, J = 9.4, 1.8 Hz, 1 H, HAr), 7.44 
(bd, J = 8.2, Hz, 2 H, HAr), 2.48 (bs, 3 H, CH3) ppm;13C NMR (101 MHz, 
CDCl3): δC = 153.7 (C, CAr), 151.8 (q, J = 2.1 Hz, C‒OCF3), 149.9 (C, CAr), 
147.3 (C, CAr), 137.5 (CH, CHAr), 133.8 (C, CAr), 133.2 (C, CAr), 132.2 (2 × 
CH, CHAr), 123.2 (C, CAr), 122.7 (CH, CHAr), 120.9 (2 × CH, CHAr), 122.5 
(q, J = 138.1 Hz, OCF3), 119.7 (q, J = 146.5 Hz, CF3), 118.4 (CH, CHAr), 
18.3 (CH3) ppm; 19F NMR (376 MHz, CDCl3): δF = ‒57.5, ‒68.2 ppm; 
HRMS (ESI): m/z calcd. for C18H11F6N4O [M+H]+ 413.0832; found 
413.0829. 
4-(Phenyl)ethynyl)-2-(trifluoromethyl)pyrido[1,2-e]purine (27a). 
According to GP4, the reaction was accomplished with compound 17a (52 
mg, 183 μmol) and phenylacetylene. The crude product was purified by 
column chromatography (SiO2, petroleum ether : CH2Cl2 4:6) to give 
compound 27a as a yellow solid (65 mg, 75%). m.p.: 216-218 °C; IR (neat): 
ṽ = 3106, 2209, 1637, 1574, 1287, 1120, 1128, 954, 755, 686, 598 cm–1; 
1H NMR (400 MHz, CDCl3): δH = 8.87(d, J = 6.9 Hz, 1 H, HAr), 7.89 (d, J = 
9.4 Hz, 1 H, HAr), 7.81 (d, J = 7.2 Hz, 2 H, HAr), 7.73 (t, J = 7.9 Hz, 1 H, 
HAr), 7.55‒7.35 (m, 3 H, HAr), 7.14 (t, J = 6.7 Hz, 1 H, HAr) ppm; 13C NMR 
(101 MHz, CDCl3): δC = 151.0 (C, CAr), 147.6 (q, J = 37.4 Hz, C‒CF3), 
146.6 (C, CAr), 142.4 (C, CAr), 136.3 (C, CAr), 134.5 (CH, CHAr), 133.0 (2 × 
CH, CHAr) , 130.4 (CH, CHAr), 128.6 (2 × CH, CHAr), 125.6 (CH, CHAr), 
121.3 (C, CAr), 120.1 (q, J = 274.6 Hz, CF3), 119.3 (CH, CHAr), 113.3 (CH, 
CHAr), 101.3 (C, ≡C), 84.5 (C, C≡) ppm; 19F NMR (376 MHz, CDCl3): δF = 
‒68.0 ppm; HRMS (ESI): m/z calcd. for C18H9F3N4 [M+H]+ 339.0852; found 
339.0849. 
4-((4-Methylphenyl)ethynyl)-2-(trifluoromethyl)pyrido[1,2-e]purine 
(28a). According to GP4, the reaction was accomplished with compound 
17a (52 mg, 183 μmol) and 4-ethynyltoluene. The crude product was 
purified by column chromatography (SiO2, petroleum ether : EtOAc 5:5) to 
give compound 28a as a yellow solid (45 mg, 70%). m.p.: 236-237 °C; IR 
(neat): ṽ = 3455, 3015, 2946, 2205, 1739, 1367, 1407, 1216, 1149, 1128, 
1087, 952, 817, 766 cm–1; 1H NMR (400 MHz, CDCl3/TMS): δH = 8.85 (br 
d, J = 6.9 Hz, 1 H, HAr), 7.87 (d, J = 9.4 Hz, 1 H, HAr), 7.80‒7.60 (m, 3 H, 
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HAr), 7.23 (br d, J = 7.7 Hz, 2 H, HAr), 7.12 (br t, J = 6.0 Hz, 1 H, HAr), 2.41 
(s, 3 H, CH3) ppm; 13C NMR (101 MHz, CDCl3): δC = 150.9 (C, CAr), 147. 
5 (q, J = 37.3 Hz, C‒CF3), 146.5 (C, CAr), 142.6 (C, CAr), 141.1 (C, CAr), 
136.2 (C, CAr), 134.3 (CH, CHAr), 133.0 (2 × CH, CHAr), 129.4 (2 × CH, 
CHAr), 125.6 (CH, CHAr), 120.1 (q, J = 274.9 Hz, CF3), 119.3 (CH, CHAr), 
118.2 (C, CAr), 113.3 (CH, CHAr), 102.0 (C, ≡C), 84.2 (C, C≡), 21.9 (CH3) 
ppm; 19F NMR (376 MHz, CDCl3): δF = ‒68.0 ppm; HRMS (ESI): m/z calcd. 
for C19H12F3N4 [M+H]+ 353.1009; found 353.1007. 
4-((4-Fluorophenyl)ethynyl)-2-(trifluoromethyl) pyrido[1,2-e]purine 
(29a). According to GP4, the reaction was accomplished with compound 
17a (52 mg, 183 μmol) and 1-ethynyl-4-fluorobenzene. The crude product 
was purified by column chromatography (SiO2, petroleum ether : EtOAc 
4:6) to give compound 29a as a yellow solid (41 mg, 63%). m.p.: 194-
195 °C; IR (neat): ṽ = 3851, 3127, 2921, 2850, 2213, 1969, 1509, 1223, 
1142, 802 cm–1; 1H NMR (400 MHz, CDCl3): δH = 8.86 (d, J = 7.0 Hz, 1 H, 
HAr), 7.88 (br d, J = 9.4 Hz, 1 H, HAr), 7.84-7.77 (m, 2 H, HAr), 7.74 (ddd, J 
= 9.4, 6.7, 1.4 Hz, 1 H, HAr), 7.20-7.07 (m, 3 H, HAr) ppm; 13C NMR (101 
MHz, CDCl3): δC = 163.9 (d, 1J = 253.1 Hz, C, C‒F), 151.0 (C, CAr), 147.6 
(q, 2J = 37.6 Hz, C‒CF3), 146.6 (C, CAr), 142.2 (C, CAr), 136.2 (C, CAr), 
135.2 (d, 3J = 8.8 Hz, CH, CH=C‒C‒F), 134.6 (CH, CHAr), 125.6 (CH, 
CHAr), 120.1 (q, 1J = 274.8 Hz, CF3), 119.3 (CH, CHAr), 117.4 (d, 4J = 3.6 
Hz, C, C‒C=C‒C‒F), 116.1 (d, 2J = 22.3 Hz, CH, CH‒C‒F), 113.3 (CH, 
CHAr), 100.1 (C, ≡C), 84.3 (C, C≡) ppm; 19F NMR (376 MHz, CDCl3): δF = 
‒68.0, ‒107.1; HRMS (ESI): m/z calcd. for C18H9F4N4 [M+H]+ 357.0758; 
found 357.0759. 
4-((4-Methoxyphenyl)ethynyl)-2-(trifluoromethyl) pyrido[1,2-e]purine 
(30a). According to GP4, the reaction was performed with compound 17a 
(46.6 mg, 171 μmol) and 4-ethynylanisole. The crude product was purified 
by column chromatography (SiO2, petroleum ether : EtOAc 5:5) to give 
compound 30a as a yellow solid (54 mg, 86%). m.p.: 208-210 °C; IR (neat): 
ṽ = 3456, 3015, 2945, 2195, 1738, 1572, 1365, 1251, 1295, 1365, 1216, 
1125, 1086, 954, 829, 763 cm–1; 1 H NMR (400 MHz, CDCl3): δH = 8.85 (br 
d, J = 6.5 Hz, 1 H, HAr), 7.87 (d, J = 9.2 Hz, 1 H, HAr), 7.76 (d, J = 8.3 Hz, 
2 H, HAr anis), 7.72 (t, J = 6.5 Hz, 1 H, HAr), 7.12 (br t, J = 6.5 Hz, 1 H, HAr), 
6.94 (d, J = 8.3 Hz, 2 H, HAr anis), 3.87 (s, 3 H, OCH3) ppm; 13 C NMR (101 
MHz, CDCl3): δC = 161.5 (C, CO), 150.8 (C, CAr), 147.6 (q, J = 37.2 Hz, C‒
CF3), 146.4 (C, CAr), 142.9 (C, CAr), 136.0 (C, CAr), 134.9 (2 × CH, CHAr), 
134.2 (CH, CHAr), 125.6 (CH, CHAr), 120.2 (q, J = 274.9 Hz, CF3), 119.3 
(CH, CHAr), 114.3 (2 × CH, CHAr), 113.2 (CH, CHAr), 102.3 (C, ≡C), 84.1 
(C, C≡), 55.6 (CH3, OCH3) ppm; 19F NMR (376 MHz, CDCl3): δF = ‒68.0; 
HRMS (ESI): m/z calcd. for C19H12F3N4O [M+H]+ 369.0958; found 
369.0957. 
4-[2-(3-Methoxyphenyl)ethynyl]-2-(trifluoromethyl)pyrido[1,2-
e]purine (32a). According to GP4, the reaction was achieved with 
compound 17a (52 mg, 183 μmol) and 3-ethynylanisole. The crude product 
was purified by column chromatography (SiO2, petroleum ether : EtOAc 
5:5) to give compound 32a as a yellow solid (49.5 mg, 73%). m.p.: 194-
195°C; IR (neat): ṽ = 3456, 3015, 2969, 2220, 1739, 1640, 1365, 1269, 
1216, 1135, 1034, 907, 852 cm–1; 1 H NMR (400 MHz, CDCl3): δH = 8.87 
(d, J = 6.9 Hz, 1 H, HAr), 7.89 (d, J = 9.3 Hz, 1 H, HAr), 7.78-7.69 (m, 1 H, 
HAr), 7.41 (d, J = 7.5 Hz, 1 H, HAr), 7.34 (t, J = 6.7 Hz, 2 H, HAr), 7.14 (t, J 
= 6.7 Hz, 1 H, HAr), 7.03 (d, J = 8.0 Hz, 1 H, HAr), 3.86 (s, 3 H, OCH3) ppm; 
13C NMR (101 MHz, CDCl3): δC = 159.5 (C, CO), 151.0 (C, CAr), 147.6 (q, 
J = 38.1 Hz, C‒CF3), 146.6 (C, CAr), 142.4 (C, CAr), 136.3 (C, CAr), 134.5 
(CH, CHAr), 129.7 (CH, CHAr), 125.7 (CH, CHAr), 125.6 (CH, CHAr), 122.2 
(C, CAr), 120.1 (q, J = 274.8 Hz, CF3), 119.3 (CH, CHAr), 117.6 (CH, CHAr), 
117.2 (CH, CHAr), 113.3 (CH, CHAr), 101.3 (C, ≡C), 84.3 (C, C≡), 55.7 (CH3, 
OCH3) ppm; 19F NMR (376 MHz, CDCl3): δF = ‒68.0 ppm; HRMS (ESI): 
m/z calcd. for C19H12F3N4O [M+H]+ 369.0958; found 369.0956. 
4-((2-Methoxyphenyl)ethynyl)-2-(trifluoromethyl)pyrido[1,2-e]purine 
(31a). According to GP4, the reaction was carried out with compound 17a 
(52 mg, 183 μmol) and 2-ethynylanisole. The crude product was purified 
by column chromatography (SiO2, petroleum ether : EtOAc 5:5) to give 
compound 31a as a yellow solid (35 mg, 52%). m.p.: 204-205 °C; IR (neat): 
ṽ = 3455, 3015, 2922, 2200, 1738, 1637, 1409, 1216, 905, 503 cm–1;1H 
NMR (250 MHz, CDCl3): δH = 8.84 (d, J = 6.9 Hz, 1 H, HAr), 7.86 (d, J = 
9.3 Hz, 1 H, HAr), 7.76-7.67 (m, 2 H, HAr), 7.51-7.36 (m, 1 H, HAr), 7.11 (t, 
J = 6.7 Hz, 1 H, HAr), 7.04-6.90 (m, 2 H, HAr), 4.00 (s, 3 H, OCH3) ppm; 13C 
NMR (63 MHz, CDCl3): δC = 161.3 (C, CO), 150.9 (C, CAr), 147.6 (q, J = 
37.4 Hz, C‒CF3), 146.4 (C, CAr), 142.7 (C, CAr), 136.2 (C, CAr), 134.8 (CH, 
CHAr), 134.3 (CH, CHAr), 132.2 (CH, CHAr), 125.6 (CH, CHAr), 120.6 (CH, 
CHAr), 120.1 (q, J = 274.8 Hz, CF3), 119.3 (CH, CHAr), 113.2 (CH, CHAr), 
110.9 (CH, CHAr), 110.6 (C, CAr), 98.6 (C, ≡C), 88.4 (C, C≡), 56.1 (CH3, 
OCH3) ppm; 19F NMR (235 MHz, CDCl3): δF = ‒68.0 ppm; HRMS (ESI): 
m/z calcd. for C19H12F3N4O [M+H]+ 369.2958; found 369.0958. 
4-((4-Fluoro-3-methylphenyl)ethynyl)-2-(trifluoromethyl) pyrido[1,2-
e]purine (34a). According to GP4, the reaction was performed with 
compound 17a (52 mg, 183 μmol) and 4-ethynyl-1-fluoro-2-
methylbenzene. The crude product was purified by column 
chromatography (SiO2, petroleum ether : EtOAc 5:5) to give compound 
34a as a yellow solid (41 mg, 60%). m.p.: 192-193 °C; IR (neat): ṽ = 3120, 
2920, 2849, 2210, 1968, 1510, 1222, 1142, 800, 803 cm–1; 1H NMR (250 
MHz, CDCl3): δH = 8.86 (dt, J = 6.9, 1.2 Hz, 1 H, HAr), 7.89 (dt, J = 9.4, 1.2 
Hz, 1 H, HAr), 7.78-7.57 (m, 3 H, HAr), 7.13 (td, J = 6.9, 1.2 Hz, 1 H, HAr), 
7.06 (t, J = 9.4 Hz, 1 H, HAr), 2.32 (d, J = 2.0 Hz, 3 H CH3) ppm; 13C NMR 
(63 MHz, CDCl3): δC = 162.6 (d, 1J = 251.7 Hz, C, C‒F), 151.0 (C, CAr), 
147.6 (q, 2J = 37.3 Hz, C‒CF3), 146.5 (C, CAr), 142.4 (C, CAr), 136.5 (d, 3J 
= 6.0 Hz, CH, CH=C‒C‒F), 136.2 (C, CAr), 134.5 (CH, CHAr), 132.5 (d, 3J 
= 6.0 Hz, CH, CH=C‒C‒F), 125.9 (d, 2J = 18.3 Hz, C, CH3‒C‒C‒F), 125.6 
(CH, CHAr), 120.1 (q, 1J = 274.7 Hz, CF3), 119.3 (CH, CHAr), 117.0 (d, 4J = 
3.8 Hz, C, C‒C=C‒C‒F), 115.7 (d, 2J = 23.3 Hz, CH, CH‒C‒F), 113.3 (CH, 
CHAr), 100.7 (C, ≡C), 84.1 (C, C≡), 14.5 (d, 3J = 3.5 Hz, F‒C‒CH3) ppm; 
19F NMR (235 MHz, CDCl3): δF = ‒68.0, ‒111.5 ppm; HRMS (ESI): ): m/z 
calcd. for C19H11F4N4 [M+H]+ 371.0914; found 371.0914. 
4-(3,3-Dimethylbut-1-yn-1-yl)-2-(trifluoromethyl)pyrido[1,2-e]purine 
(33a). According to GP4, the reaction was performed with compound 17a 
(52 mg, 183 μmol) and tert-butylacetylene. The crude product was purified 
by column chromatography (SiO2, petroleum ether : EtOAc 6:4) to give 
compound 33a as a yellow solid (38 mg, 65%). m.p.: 228-229 °C; IR (neat): 
ṽ = 3458, 2925, 2852, 2220, 1738, 1640, 1488, 1365, 1270, 1153, 900, 
762, 762, 743 cm–1; 1 H NMR (400 MHz, CDCl3): δH = 8.83 (d, J = 6.8 Hz, 
1 H, HAr), 7.86 (d, J = 9.4 Hz, 1 H, HAr), 7.78‒7.64 (m, 1 H, HAr), 7.10 (t, J 
= 6.8 Hz, 1 H, HAr), 1.49 (s, 9 H) ppm; 13C NMR (101 MHz, CDCl3): δC = 
150.8 (C, CAr), 147.5 (q, J = 37.2 Hz, C‒CF3), 146.3 (C, CAr), 143.3 (C, 
CAr), 136.3 (C, CAr), 134.1 (CH, CHAr), 125.5 (CH, CHAr), 120.1 (q, J = 
274.7 Hz, CF3), 119.3 (CH, CHAr), 113.1 (CH, CHAr), 112.0 (C, ≡C), 75.3 
(C, C≡), 30.6 (CH3), 28.9 (C, C(CH3)3) ppm; 19F NMR (376 MHz, CDCl3): 
δF = ‒68.0 ppm; HRMS (ESI): m/z calcd. for C16H13F3N4 [M+H]+ 319, 1165; 
found 319.1164. 
7-Methyl-4-(p-tolylethynyl)-2-(trifluoromethyl)pyrido[1,2-e]purine 
(28b). According to GP4, the reaction was performed with compound 17b 
(52 mg, 183 μmol) and 4-ethynyltoluene. The crude product was purified 
by column chromatography (SiO2, petroleum ether : EtOAc 7:3) to give 
compound 28b as a yellow solid (40 mg, 60%). m.p.: 198-200 °C; IR (neat): 
ṽ = 3455, 3015, 2946, 2205, 1739, 1367, 1407, 1216, 1149, 1128, 1087, 
952, 817, 766 cm–1; 1H NMR (400 MHz, CDCl3): δH = 8.69 (d, J = 7.0 Hz, 
1 H, HAr), 7.68 (d, J = 8.0 Hz, 2 H, HAr), 7.57 (s, 1 H, HAr), 7.21 (d, J = 7.9 
Hz, 2 H, HAr), 6.93 (d, J = 7.9 Hz, 1 H, HAr), 2.55 (s, 3 H, CH3), 2.40 (s, 3 
H, CH3) ppm; 13C NMR (101 MHz, CDCl3): δC = 151.4 (C, CAr), 147.1 (q, J 
= 37.5 Hz, C‒CF3), 146.7 (C, CAr), 146.6 (C, CAr), 141.7 (C, CAr), 140.9 (C, 
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CAr), 136.5 (C, CAr), 132.9 (2 × CH, CHAr), 129.4 (2 × CH, CHAr), 124.4 (CH, 
CHAr), 120.1 (q, J = 274.7 Hz, CF3), 118.2 (C, CAr), 117.0 (CH, CHAr), 116.2 
(CH, CHAr), 101.4 (C, ≡C), 84.2 (C, C≡), 22.6 (CH3), 21.9 (CH3) ppm; 19F 
NMR (376 MHz, CDCl3): δF = ‒68.0 ppm; HRMS (ESI): m/z calcd. for 
C20H14F3N4 [M+H]+ 367.1165; found 367.1161. 
4-((3-Methoxyphenyl)ethynyl)-7-methyl-2-(trifluoromethyl) 
pyrido[1,2-e]purine (32b). According to GP4, the reaction was achieved 
with compound 17b (52 mg, 183 μmol) and 3-ethynylanisole. The crude 
product was purified by column chromatography (SiO2, petroleum ether : 
EtOAc 6:4) to give compound 32b as a yellow solid (48 mg, 69%). m.p.: 
193-194 °C; IR (neat): ṽ = 3455, 3015, 2945, 2202, 1739, 1650, 1571, 
1365, 1249, 1216, 1161, 1092, 789 cm–1; 1H NMR (400 MHz, CDCl3): δH = 
8.71 (d, J = 7.0 Hz, 1 H, HAr), 7.61‒7.59 (m, 1 H, HAr), 7.40 (dt, J = 7.6, 1.3 
Hz 1 H, HAr), 7.33 (d, J = 8.1 Hz, 1 H, HAr), 7.31‒7.29 (m, 1 H, HAr), 7.01 
(ddd, J = 8.6, 2.7, 1.5 Hz, 1 H, HAr), 6.95 (dd, J = 7.0, 1.5 Hz, 1 H, HAr), 
3.85 (s, 3 H, OCH3), 2.57 (s, 3 H, CH3) ppm;13C NMR (101 MHz, CDCl3): 
δC = 159.4 (C, CO), 151.5 (C, CAr), 147.1 (q, J = 37.6 Hz, C‒CF3), 146.9 
(C, CAr), 146.8 (C, CAr), 141.4 (C, CAr), 136.6 (C, CAr), 129.7 (CH, CHAr), 
125.7 (CH, CHAr), 124.5 (CH, CHAr), 122.3 (C, CAr), 120.1 (q, J = 274.8 Hz, 
CF3), 117.5 (CH, CHAr), 117.2 (CH, CHAr), 117.1 (CH, CHAr), 116.3 (CH, 
CHAr), 100.7 (C, ≡C), 84.3 (C, C≡), 55.6 (CH3, OCH3), 22.6 (CH3) ppm; 19F 
NMR (376 MHz, CDCl3): δF = ‒67.9 ppm; HRMS (ESI): m/z calcd. for 
C20H14F3N4O [M+H]+ 383.1114; found 383.1114. 
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